DGAP-Adhoc

Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)

DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS) 03-Feb-2022 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)

Osaka, Japan, February 3, 2022 - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2022, as below.

1. Revised Forecast for Full Year Consolidated Financials for the Fiscal Year Ending March 31, 2022

(millions of yen)

	Revenue	Core Operating Profit	Operating profit	Profit before income taxes	Net profit attributable to owners of the Company	Basic earnings per share	Core EPS
Previous Forecast (A)*	3,370,000	930,000	488,000	352,000	184,300	117.35 yen	394 yen
Revised Forecast (B)	3,510,000	970,000	515,000	385,000	242,500	154.99 yen	416 yen
Discrepancy (B-A)	+140,000	+40,000	+27,000	+33,000	+58,200	―	―
Change %	+4.2%	+4.3%	+5.5%	+9.4%	+31.6%	―	―

 

^* Announced on October 28, 2021.